[go: up one dir, main page]

WO2011120040A3 - Thrombin inhibiting compositions - Google Patents

Thrombin inhibiting compositions Download PDF

Info

Publication number
WO2011120040A3
WO2011120040A3 PCT/US2011/030190 US2011030190W WO2011120040A3 WO 2011120040 A3 WO2011120040 A3 WO 2011120040A3 US 2011030190 W US2011030190 W US 2011030190W WO 2011120040 A3 WO2011120040 A3 WO 2011120040A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibiting compositions
thrombin inhibiting
thrombin
thrombosis
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2011/030190
Other languages
French (fr)
Other versions
WO2011120040A2 (en
Inventor
Marcel Thurk
Andreas Schwienhorst
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Matrix Pharmaceutical Inc
Original Assignee
Matrix Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Matrix Pharmaceutical Inc filed Critical Matrix Pharmaceutical Inc
Publication of WO2011120040A2 publication Critical patent/WO2011120040A2/en
Publication of WO2011120040A3 publication Critical patent/WO2011120040A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/02—Linear peptides containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21005—Thrombin (3.4.21.5)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel compounds and methods of treating or preventing thrombosis or a thrombosis-associated disease.
PCT/US2011/030190 2010-03-26 2011-03-28 Thrombin inhibiting compositions Ceased WO2011120040A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31793810P 2010-03-26 2010-03-26
US61/317,938 2010-03-26

Publications (2)

Publication Number Publication Date
WO2011120040A2 WO2011120040A2 (en) 2011-09-29
WO2011120040A3 true WO2011120040A3 (en) 2011-12-29

Family

ID=44673909

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/030190 Ceased WO2011120040A2 (en) 2010-03-26 2011-03-28 Thrombin inhibiting compositions

Country Status (1)

Country Link
WO (1) WO2011120040A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455671B1 (en) * 1994-06-17 2002-09-24 Abbott Laboratories Thrombin inhibitors, the preparation and use thereof
US7081447B2 (en) * 2001-09-10 2006-07-25 Novel Science International Gmbh Organic compounds with biological activity as thrombin inhibitors and use thereof
US7423021B2 (en) * 2003-01-15 2008-09-09 Nsci Novel Science International Gmbh Peptidic thrombin inhibitors

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455671B1 (en) * 1994-06-17 2002-09-24 Abbott Laboratories Thrombin inhibitors, the preparation and use thereof
US7081447B2 (en) * 2001-09-10 2006-07-25 Novel Science International Gmbh Organic compounds with biological activity as thrombin inhibitors and use thereof
US7423021B2 (en) * 2003-01-15 2008-09-09 Nsci Novel Science International Gmbh Peptidic thrombin inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DANIEL RIESTER ET AL.: "Thrombin inhibitors identified by computer-assisted multiparameter design", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 102, no. 24, 2005, pages 8597 - 8602 *

Also Published As

Publication number Publication date
WO2011120040A2 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
WO2012142498A3 (en) Mif inhibitors and their uses
HK1210696A1 (en) Irak inhibitors and uses thereof
EP2877159B8 (en) Efflux inhibitor compositions and methods of treatment using the same
WO2011060066A9 (en) Methods of treating or preventing stent thrombosis
WO2014052836A3 (en) Methods and compositions for treating infection
IN2012DN03883A (en)
WO2012158843A3 (en) Kinase inhibitors
GB201004311D0 (en) New enzyme inhibitor compounds
ZA201302625B (en) Methods and compositions for treating hemophilia b
IL229072A0 (en) 1, 3-oxazines as 1bace and/or 2bace inhibitors
WO2012156537A9 (en) Lysine demethylase inhibitors such as cyclylcylopropamine derivatives for use in the treatment of thrombosis and cardiovascular diseases
GEP20156341B (en) Anticoagulant antidotes
WO2011130222A3 (en) Compositions and methods comprising variant proteases
ZA201304940B (en) Granzyme b inhibitor compositions, methods and uses for promoting wound healing
EP2729464B8 (en) Cyclopropyl-fused-1,3-thiazepines as bace 1 and/or bace 2 inhibitors
EP2403340A4 (en) Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
IL223865A0 (en) Calcium salts of dihydrooroorotate dehydrogenase inhibitors, compositions comprising the same and uses thereof
WO2014093988A3 (en) Methods and compositions for inhibiting cnksr1
WO2012017321A3 (en) Treatment for dyslipidemia
EP2672965A2 (en) Treatment and prevention of cardiovascular disease and thrombosis
WO2012065059A3 (en) Treatment of atherosclerosis with bmp-alk3 antagonists
WO2012024670A3 (en) Composition and methods for treating glioblastoma
WO2011110367A3 (en) Method of screening for htra protease inhibitors useful for prophylaxis and therapy of a bacterial infection
WO2011109131A3 (en) Distributed-type markov chain monte carlo
PH12014500538A1 (en) Methods and compositions for treating leukemia

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11760372

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 15.01.2013.)

122 Ep: pct application non-entry in european phase

Ref document number: 11760372

Country of ref document: EP

Kind code of ref document: A2